Corona Remedies IPO is a book-built issue worth ₹655.37 crore, comprising an entirely offer-for-sale of 0.62 crore equity shares. The subscription window opens on December 8, 2025, and closes on December 10, 2025, with allotment expected on December 11, 2025.
The IPO is set to list on both BSE and NSE, tentatively on December 15, 2025. The price band is fixed at ₹1008–₹1062 per share, and the minimum retail investment stands at ₹14,868 for one lot of 14 shares at the upper price band.
Corona Remedies IPO received an overall subscription of 18.11 times. By 10:44:37 AM on December 10, 2025 (Day 3), the retail portion was subscribed 10.22 times, the QIB (excluding anchor) segment 1.85 times, and the NII category an impressive 58.94 times.
The Corona Remedies IPO, valued at ₹655.37 crore, is a book-built issue consisting solely of an offer-for-sale of 0.62 crore shares. Investors can subscribe between December 8 and December 10, 2025, with allotment slated for December 11, 2025.
The shares are expected to debut on the BSE and NSE on December 15, 2025. The IPO’s price band ranges from ₹1008 to ₹1062 per share, and retail applicants must invest a minimum of ₹14,868 for a lot of 14 shares at the upper price band.
As of 10:44:37 AM on December 10, 2025 (Day 3), the Corona Remedies IPO saw a total subscription of 18.11 times. Retail investors subscribed 10.22 times, QIBs (Ex-Anchor) 1.85 times, while the NII category recorded a strong 58.94 times subscription.
The table below breaks down the Corona Remedies share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| QIB Shares Offered | 30,56,533 (49.53%) |
| – Anchor Investor Shares Offered | 18,34,804 (29.73%) |
| – QIB (Ex. Anchor) Shares Offered | 12,21,729 (19.80%) |
| NII (HNI) Shares Offered | 9,16,960 (14.86%) |
| – bNII > ₹10L | 6,11,307 (9.91%) |
| – sNII < ₹10L | 3,05,653 (4.95%) |
| Retail Shares Offered | 21,39,573 (34.67%) |
| Employee Shares Offered | 58,036 (0.94%) |
| Total Shares Offered | 61,71,102 (100.00%) |
| Category | Subscription (times) |
| Qualified Institutional Buyers | 1.88 |
| Non-Institutional Investors | 61.73 |
| Retail Individual Investors | 10.63 |
| Total shares | 18.91 |
Note: The subscription details are as of Dec 10, 2025
Corona Remedies Limited is a pharmaceutical company engaged in developing, manufacturing, and marketing products across women’s health, cardiology, pain management, urology, and other key therapeutic areas.
As of June 30, 2025, the company’s product portfolio spans 71 brands covering segments such as women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty categories including vitamins/minerals/nutrition, gastrointestinal, and respiratory care.
Corona Remedies operates a strong pan-India marketing and distribution network, supported by 2,671 medical representatives across 22 states. This wide reach enables strong engagement with healthcare professionals and hospitals, reinforces its footprint in the Indian Pharmaceutical Market (IPM), and enhances penetration in targeted therapies.
The company also runs two manufacturing facilities in Gujarat, with a combined installed formulation capacity of 1,285.44 million units per year.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 10, 2025, 10:58 AM IST
Nikitha Devi
Nikitha is a content creator with 7+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
